PP
JNP

PDT Partners’s Juniper Pharmaceuticals, Inc. Common Stock JNP Stock Holding History

PDT Partners’s Portfolio JNP Stock Details JNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-19,000
Closed -$224K – 1167
2015
Q3 		$224K Buy
19,000
+3,600
+23% +$39.8K 0.01% 1121
2015
Q2 		$141K Buy
+15,400
New +$116K ﹤0.01% 1280
2014
Q4 		– Sell
-10,200
Closed -$60K – 1264
2014
Q3 		$60K Sell
10,200
-3,500
-26% -$21.3K ﹤0.01% 1252
2014
Q2 		$94K Buy
+13,700
New +$91.7K ﹤0.01% 1367

Other funds holding JNP

BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
EI
EAM Investors Solana Beach, California $866M AUM 377.14% 1-Year Est. Return
BA
BlackRock Advisors Wilmington, Delaware $98.8B AUM 39.77% 1-Year Est. Return

PDT Partners's JNP Position: Q4 2015 in Review

PDT Partners sold out of Juniper Pharmaceuticals, Inc. Common Stock (JNP) in Q4 2015, closing a stake of 19,000 shares — an estimated $224K sold.

PDT Partners first reported a position in JNP in Q2 2014 and held it in 4 quarters. The position peaked at $224K in Q3 2015. 54 funds tracked by Wall St. Rank hold JNP as of Q4 2015.

  • PDT Partners reported no remaining Juniper Pharmaceuticals, Inc. Common Stock position as of Q4 2015 after selling out during the quarter.
  • PDT Partners sold 19,000 Juniper Pharmaceuticals, Inc. Common Stock shares in Q4 2015, an estimated $224K.
  • PDT Partners first reported a position in Juniper Pharmaceuticals, Inc. Common Stock in Q2 2014 and held it in 4 quarters.
  • PDT Partners's Juniper Pharmaceuticals, Inc. Common Stock position peaked at $224K in Q3 2015.
  • 54 funds tracked by Wall St. Rank held Juniper Pharmaceuticals, Inc. Common Stock as of Q4 2015.

Based on PDT Partners's 13F filing for Q4 2015, filed 16 Feb 2016.